Home | Welcome to Contract Pharma   
Last Updated Wednesday, August 27 2014
Print RSS Feed

Actavis to Acquire Akorn Products



Published April 21, 2014
Related Searches: Development Pharma www.contractpharma.com Manufacturing
Actavis plc has entered into agreements with Akorn, Inc. and Hi-Tech Pharmacal Co. to acquire four marketed products and one product in development, for an undisclosed cash consideration. The closing of the agreements are contingent upon Akorn's acquisition of Hi-Tech. Last August, Akorn entered an agreement to acquire Hi-Tech for $640 million in cash.

The marketed products include Ciprofloxacin Hydrochloride Ophthalmic Solution, Levofloxacin Ophthalmic Solution, Lidocaine Hydrochloride Jelly, and Lidocaine/Prilocaine Topical Cream. 

"The acquisition of these products will complement our expanding portfolio of topical and ophthalmic generic products, and further strengthen our position as a leader in developing and marketing the complex, high-barrier products that provide enhanced value," said Siggi Olafsson, president, Actavis Pharma.



blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On